Xatmep (Methotrexate) Patent Expiration, LOE Window & CMS Spending
Xatmep (Methotrexate) by Azurity: FDA Orange Book LOE 2033-01-02, 9 AB generics, $3.2M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Azurity |
| FDA Application & Pathway | N208400 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2033-01-02 |
| Orange Book Patents (*PED Extensions) | 7 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 9 |
| 2024 CMS Total Public Spend | $3.2M |
| 2024 Medicare Part D Spend | $246K |
| 2024 Medicaid Spend | $3.0M |
| Reported Wholesale Price Change (CA SB 17) | 6 WAC filings (max 24.3% 2-yr change) |